Eagle Pharmaceuticals, Inc.
OTC: EGRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Michael Graves
- Employees
- 141
- Headquarters
- Woodcliff Lake, United States
- IPO year
- 2014
- Market cap
- $8.4M
- Website
- https://www.eagleus.com
Loading EGRX…
Loading profile data…Frequently asked questions about EGRX
What does Eagle Pharmaceuticals, Inc. (EGRX) do?
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for...
Where does EGRX trade?
Eagle Pharmaceuticals, Inc. (EGRX) trades on the Other OTC.
What sector is EGRX in?
Eagle Pharmaceuticals, Inc. (EGRX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Eagle Pharmaceuticals, Inc.?
Michael Graves is the chief executive officer of Eagle Pharmaceuticals, Inc. (EGRX).
Where is Eagle Pharmaceuticals, Inc. headquartered?
Eagle Pharmaceuticals, Inc. is headquartered in United States.
Does EGRX pay a dividend?
Eagle Pharmaceuticals, Inc. (EGRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EGRX go public?
Eagle Pharmaceuticals, Inc. (EGRX) completed its initial public offering in 2014.